Company Analysis
Sign in

Haoxi Health Technology Limited (HAO)

Nasdaq: HAO · Services-Advertising Agencies · Beijing · filing with the SEC since 2023
Full chart Alerts Compare
Grade4.9
◀ Past 5.8● Present 4.3▶ Future 4.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Haoxi Health Technology Limited

Nine metrics read from its own filings, by tense
Headline grade
4.9/10
◀ Past5.830% of the headline
● Present4.340% of the headline
▶ Future4.730% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.8/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
7.5/10

Has it survived what it has been through?

No warning events in its filings since 2023.

weight 33% of this tense · 75th percentile among 10 sector filers · read for itself

From the record

Haoxi Health Technology Limited's filings since 2023 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
7.1/10

What has it actually done, year after year?

+35.7% a year over 5 filed years; profitable in 4 of 5.

weight 45% of this tense · 71st percentile among 10 sector filers · read for its customers

From the record

Haoxi Health Technology Limited's 5 filed years say what it did: revenue went from $16 million in fiscal 2022 to $55 million in fiscal 2026, up 35.7% a year; it rose in 3 of 4 years; the deepest fall was 32% from fiscal 2024 to fiscal 2025; net income was positive in 4 of 5 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span35.7%top 5% of its family
  • the share of years revenue rosetop 15% of its family
  • the share of filed years with a profittop 30% of its family
  • the deepest fall from a revenue peak32.4%bottom 35% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
0.5/10

How has it treated the people who own it?

SI estimate 0.5/10, confidence 35 of 100 (one part).

weight 22% of this tense · 5th percentile among 10 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 5% of 10 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 10 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Haoxi Health Technology Limited's shareholder treatment is put at 0.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 5% of 10 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.3/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
3.7/10

Is it financially healthy right now?

ROE -53%: lost 53¢ per shareholder dollar. Leverage 17%: owes 17¢ per asset dollar.

weight 33% of this tense · 37th percentile among 9 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2026-06-30, Haoxi Health Technology Limited lost about 53 cents for every dollar of shareholders' money, and gross profitability: its products earned about 3 cents per dollar of everything the company owns. Leverage: it owed about 17 cents per dollar of assets, and net share issuance: its share count grew 2536.8% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 17% of its family
  • return on equitybottom 31% of its family
  • gross profit against assetsbottom 28% of its family
  • the share count against the year beforebottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
4.7/10

How strong is its position in its industry?

bottom 47% of 10 in its family; net margin -17.4%.

weight 45% of this tense · 47th percentile among 10 sector filers · read for its customers

From the record

Haoxi Health Technology Limited's standing among 10 graded names in its industry family: revenue of $55 million in fiscal 2026 ranks in the bottom 31% by size; a net margin of -17.4% ranks in the bottom 35%; revenue growth of 24.8% a year over the last 3 filed years ranks in the top 25% (its annual reports).

What it rests on

  • revenue against the family$54.8Mbottom 31% of its family
  • net margin-17.4%bottom 35% of its family
  • three-year revenue growth24.8%top 25% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
4.3/10

What are the people in charge doing?

SI estimate 4.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 5 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-19 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 5 members with one.
What the record cannot read
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-19 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
family median, 5 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Haoxi Health Technology Limited's leadership is put at 4.3 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-19 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 5 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.7/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
3.9/10

How much room does it have to grow?

bottom 39% of 10 in its family for room to expand.

weight 33% of this tense · 39th percentile among 10 sector filers · read for itself

From the record

Haoxi Health Technology Limited's room to grow, from the newest filed statements (fiscal 2026): cash of $11 million against no long-term debt tagged leaves 50.7% of its assets as net cash, top 6% of its family; cash from operations less capital spending is -4.7% of revenue (bottom 35%); a gross margin of 1.1% (bottom 15%); research spending of 0.2% of revenue (bottom 13%) (its annual report).

What it rests on

  • cash less debt against assets50.7%top 6% of its family
  • cash from operations less capital spending against revenue-4.7%bottom 35% of its family
  • gross margin1.1%bottom 15% of its family
  • research spending against revenue0.2%bottom 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
5.8/10

What could actually drive growth from here?

top 42% of 10 in its family for growth drivers.

weight 45% of this tense · 58th percentile among 10 sector filers · read for its customers

From the record

Haoxi Health Technology Limited's growth drivers, from the filed years to fiscal 2026: revenue grew 24.8% a year over the last three filed years against 35.7% over all 5, slowing (bottom 5% of its family); the newest year grew 67.2% (top 15%); research spending grew 21.5% a year (top 50%); capital spending grew 152.1% a year (top 6%) (its annual reports). Haoxi Health Technology Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span-11.0 points a yearbottom 5% of its family
  • the newest year's revenue growth67.2%top 15% of its family
  • three-year growth of research spending21.5%top 50% of its family
  • three-year growth of capital spending152.1%top 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
3.5/10

Did its newest year beat what its own record pointed to?

bottom 35% of 9 in its family for expectations against reality.

weight 22% of this tense · 35th percentile among 9 sector filers · read for its shareholders

From the record

Haoxi Health Technology Limited's newest year against its own record: revenue of $55 million in fiscal 2026 came in 55.1% above the $35 million its prior three years' pace pointed to (top 17% of its family); net income of $10 million against a prior three-year average of $2 million (bottom 6%); a net margin of -17.4% against 6% before (bottom 17%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace55.1%top 17% of its family
  • net income against the prior three years' averagefive times below its prior average or morebottom 6% of its family
  • net margin against its prior average-23.4 pointsbottom 17% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton HAO · research, not advice